Literature DB >> 6411287

A benzodiazepine antagonist is an anticonvulsant in an animal model for limbic epilepsy.

H A Robertson, M L Riives.   

Abstract

A benzodiazepine antagonist, Ro 15-1788, completely abolishes the sedative/ataxic effects of diazepam but, at the same dose (10 mg/kg, i.p.), it, like diazepam, slows the development of kindled seizures. This suggests that the anticonvulsant and sedative effects of benzodiazepines are mediated via different receptors and that Ro 15-1788 or similar compounds may be useful anticonvulsants.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6411287     DOI: 10.1016/0006-8993(83)90619-4

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

Review 1.  Intrinsic actions of the benzodiazepine receptor antagonist Ro 15-1788.

Authors:  S E File; S Pellow
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  The affinities, potencies and efficacies of some benzodiazepine-receptor agonists, antagonists and inverse-agonists at rat hippocampal GABAA-receptors.

Authors:  J A Kemp; G R Marshall; E H Wong; G N Woodruff
Journal:  Br J Pharmacol       Date:  1987-07       Impact factor: 8.739

3.  Acute and chronic effects of the benzodiazepine receptor ligand FG 7142: proconvulsant properties and kindling.

Authors:  H J Little; D J Nutt; S C Taylor
Journal:  Br J Pharmacol       Date:  1984-12       Impact factor: 8.739

Review 4.  Flumazenil in benzodiazepine antagonism. Actions and clinical use in intoxications and anaesthesiology.

Authors:  R Amrein; B Leishman; C Bentzinger; G Roncari
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Nov-Dec

5.  Effect of diazepam on cortical 5-HT release and behaviour in the guinea-pig on exposure to the elevated plus maze.

Authors:  A Rex; C A Marsden; H Fink
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Acetylcholinesterase activity in regions of mouse brain following acute and chronic treatment with a benzodiazepine inverse agonist.

Authors:  M E Appleyard; S C Taylor; H J Little
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.